Oncomine Focus Assay

Content

• Simultaneous detection of hundreds of variants across 52 genes relevant to solid tumors
• Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single workflow
• Includes solid tumor genes targeted by on-market oncology drugs and published evidence
• Content driven by the Oncomine™ Knowledgebase, which includes content aligned to approved therapies and indications
  
  

Performance

• Reproducible and sensitive detection of variants across multiple cancer types
• Compatible with as little as 10 ng sample, including FFPE fine needle biopsies and core needle aspirates
• Enables results from up to 6 samples and 2 controls per run for DNA and RNA in a single workflow
• NGS results in days rather than weeks, leveraging Ion Torrent™ sequencing technology and the Ion S5™ System or the Ion PGM™ System
• Includes Ion Select consumables and reagents manufactured to rigorous standards in our ISO 13485-compliant facility
  
  

Analytical performance summary

Across variant types, the Oncomine Focus Assay achieves high sensitivity, specificity, and reproducibility using clinical research samples sequenced on the Ion S5 System.

Table 1. Sensitivity, specificity, and reproducibility across variant types using the Oncomine Focus Assay on the Ion S5 System.

Reporting

Features enabled with Oncomine informatics:

• Prioritize variants, find the relevant few
• Call variants, identify and annotate cancer drivers
• Quickly create custom, lab-generated reports
• Customizable report templates available in 10 languages

Workflow

The Oncomine NGS oncology workflow enables you find the relevant few cancer drivers, with a report including interpretation of the findings.